Literature DB >> 9137450

Ginsenoside-Rg5 suppresses cyclin E-dependent protein kinase activity via up-regulating p21Cip/WAF1 and down-regulating cyclin E in SK-HEP-1 cells.

K Y Lee1, Y H Lee, S I Kim, J H Park, S K Lee.   

Abstract

In the present study, we report that ginsenoside-Rg5 (G-Rg5), a newly discovered diol-containing ginsenoside, blocks the cell cycle of human hepatoma SK-HEP-1 cells via the down-regulation of cyclin E-dependent kinase activity. The results from flow cytometric analyses show that G-Rg5 arrests the cell cycle of SK-HEP-1 cells at the Gl/S transition phase. The cyclin E-dependent kinase activity that has been immunoprecipitated with cyclin E-specific antibody is down-regulated in response to G-Rg5. The results from immunoblottings show that the down-regulation of cyclin E-dependent kinase activity is related to increased protein levels of p21Cip/WAF1 and to decreased protein levels of cyclin E, CDK2, and CDC25A. Collectively, these data suggest that G-Rg5 blocks cell cycle of SK-HEP-1 cells at the Gl/S transition phase by down-regulating cyclin E-dependent kinase activity and that the down-regulation of cyclin E-dependent kinase activity is caused mainly by induced CDK2 inhibitor, p21Cip/WAF1 and decreased levels of cyclin E.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9137450

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  23 in total

1.  Terpenoids as potential chemopreventive and therapeutic agents in liver cancer.

Authors:  Roslin J Thoppil; Anupam Bishayee
Journal:  World J Hepatol       Date:  2011-09-27

2.  Induced differentiation of hepatocellular carcinoma by natural products.

Authors:  Xiong-Zhi Wu; Guang-Ru Xie
Journal:  Afr J Tradit Complement Altern Med       Date:  2008-06-18

3.  Pharmacology of ginsenosides: a literature review.

Authors:  Kar Wah Leung; Alice Sze-Tsai Wong
Journal:  Chin Med       Date:  2010-06-11       Impact factor: 5.455

4.  Isolation, synthesis and structures of cytotoxic ginsenoside derivatives.

Authors:  Jun Lei; Xiang Li; Xiao-jie Gong; Yi-nan Zheng
Journal:  Molecules       Date:  2007-09-05       Impact factor: 4.411

Review 5.  Current evaluation of the millennium phytomedicine- ginseng (II): Collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine.

Authors:  Lee Jia; Yuqing Zhao; Xing-Jie Liang
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

6.  Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure-Activity Relationships, and Molecular Mechanisms of Action.

Authors:  Subhasree Ashok Nag; Jiang-Jiang Qin; Wei Wang; Ming-Hai Wang; Hui Wang; Ruiwen Zhang
Journal:  Front Pharmacol       Date:  2012-02-28       Impact factor: 5.810

7.  Anti-breast cancer activity of Fine Black ginseng (Panax ginseng Meyer) and ginsenoside Rg5.

Authors:  Shin-Jung Kim; An Keun Kim
Journal:  J Ginseng Res       Date:  2014-10-18       Impact factor: 6.060

Review 8.  Pharmacological activities of ginsenoside Rg5 (Review).

Authors:  Ming-Yang Liu; Fei Liu; Yan-Li Gao; Jia-Ning Yin; Wei-Qun Yan; Jian-Guo Liu; Hai-Jun Li
Journal:  Exp Ther Med       Date:  2021-06-06       Impact factor: 2.447

9.  Sun ginseng protects endothelial progenitor cells from senescence associated apoptosis.

Authors:  Wooseok Im; Jin-Young Chung; Jaejun Bhan; Jiyeon Lim; Soon-Tae Lee; Kon Chu; Manho Kim
Journal:  J Ginseng Res       Date:  2012-01       Impact factor: 6.060

10.  Anti-inflammatory effect of ginsenoside Rg5 in lipopolysaccharide-stimulated BV2 microglial cells.

Authors:  Yu Young Lee; Jin-Sun Park; Ji-Sun Jung; Dong-Hyun Kim; Hee-Sun Kim
Journal:  Int J Mol Sci       Date:  2013-05-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.